The DNA probes-based diagnostics market has experienced significant growth in recent years, driven by advancements in molecular biology and an increasing demand for precise diagnostic tools. DNA probes, which are single-stranded sequences designed to hybridize with specific target DNA sequences, have become indispensable in identifying various genetic and infectious diseases. Between 2015 and 2019, the market expanded at an approximate rate of 4%, and projections indicate a further growth exceeding 5% from 2020 to 2030.

A key factor propelling this growth is the rising public awareness of DNA probe technology, particularly in prenatal diagnostics and carrier detection. As more individuals become informed about the benefits of early genetic screening, the demand for such diagnostic services is anticipated to surge. Additionally, the integration of automation in diagnostic tests has streamlined processes, enhancing efficiency and accuracy, thereby creating lucrative opportunities within the market.

Market's Outlook

The market's outlook remains optimistic, with DNA probes-based technology finding extensive applications not only in diagnostics but also in fields like micro-fabrication, data handling, molecular biology, and instrumentation development. This versatility underscores the technology's broad potential and its critical role in advancing various scientific domains.

Market Analysis

In terms of market analysis, the DNA probes-based diagnostics sector is segmented by application into infectious diseases, cancer, genetic predisposition, and identity/forensics. Infectious diseases currently dominate this segmentation, reflecting the technology's efficacy in rapidly detecting and identifying pathogens. The cancer diagnostics segment is also witnessing substantial growth, driven by the need for early and accurate detection of genetic mutations associated with various cancers.

Industry News

Recent industry news highlights the increasing investments and entry of new players into the DNA probes-based diagnostics market. This influx is attributed to the growing adoption of DNA probes in novel disease identification, which has spurred both financial investments and strategic initiatives among companies aiming to capitalize on emerging opportunities.

Market Dynamics

Market dynamics reveal that while the technology offers significant advantages, challenges persist. For instance, differentiating between species using 16S rRNA sequences can be problematic due to similarities, and the expanding global library of rRNA sequences increases the risk of random hybridization events between probes and unintended target organisms. Additionally, issues such as recombination between marker and disease alleles, incorrect pedigree data, or non-paternity can lead to erroneous diagnoses, thereby hindering market growth.

Competitive Landscape

The competitive landscape is characterized by the presence of established players and the emergence of new entrants striving to gain market share. Companies are focusing on research and development to introduce innovative products and solutions. For example, BioMérieux developed the ARGENE® Solution, an automated platform dedicated to centralized laboratories for managing molecular biology tests to monitor viral infections in immunocompromised patients. This solution integrates polymerase chain reaction (PCR) technology with real-time NASBA® (Nucleic Acid Sequence-Based Amplification) technology, exemplifying the industry's commitment to advancing diagnostic capabilities.

Geographically, the United States remains a key market for DNA probes-based diagnostics, driven by a high incidence rate of genetic disorders leading to birth defects and developmental disabilities. Investments in pharmaceuticals and pharmacogenomics research and development are increasing, further bolstering the market. According to U.S. Investments in Medical and Health Research and Development, investment in medical and health research and development (R&D) rose by 27% in the five-year period from 2013 to 2017, led by industry and the federal government. The Centers for Disease Control and Prevention (CDC) reported that about 3% to 4% of newborns were born with genetic abnormalities in 2017. Additionally, the rising number of cancer cases in the country is increasing the demand for DNA probes-based diagnostics. According to the U.S. National Cancer Institute, in January 2019, there were 16.9 million cancer survivors in the U.S., with the number expected to reach 22.2 million by 2030. These factors underscore the strengthening of the market in the U.S.

In India, the market is poised for notable growth, supported by government initiatives leading to increased investments by key players. The prominence of mergers and acquisitions in the healthcare sector further supports market expansion. According to the India Brand Equity Foundation (IBEF), the value of hospital mergers and acquisitions jumped by a record 155%, reaching US$1.09 billion in 2019. The government's Pradhan Mantri Jan Arogya Yojana (PMJAY), launched on September 23, 2018, aims to provide health insurance worth US$7,124.54 to more than 100 million families annually. With a rising population, the number of infectious and other diseases is also increasing, contributing to the market's growth in India.

The rising healthcare expenditure globally supports the expansion of the DNA probes-based diagnostics market. The World Health Organization's report, "Global Spending on Health: Weathering the Storm," revealed that global spending reached US$8.3 trillion between 2000 and 2018, representing 10% of global GDP. Notably, out-of-pocket spending has persisted in low and lower-middle-income economies, representing over 40% of total health spending in 2018. This rising healthcare expenditure is augmenting the demand for DNA probes-based diagnostics. As countries converge on healthcare, the number of hospitals, clinics, and laboratories is rising. According to EHealthinsurance, in 2019, there were 6,000 hospitals in the U.S., and in 2020, the count reached 6,146, according to the American Hospital Association. This increasing number of healthcare facilities is driving the demand for DNA probes for various operations.

Read more-

Based on a new study by Fact.MR, the global bulletproof security glass market size is valued at US$ 1.41 billion in 2023 and is predicted to expand at a CAGR of 11% to reach US$ 4.51 billion by the end of 2033.

The global dozer market size is estimated to account for a valuation of US$ 5.9 billion in 2024 and is forecasted to climb to a size of US$ 10.2 billion by the end of 2034. This is because worldwide sales of dozers are set to rise at a healthy 5.6% CAGR from 2024 to 2034.

The global agricultural film market size is estimated to account for a value of US$ 11.78 billion in 2024 and is forecasted to reach US$ 21 billion by the end of 2034. Worldwide sales of agricultural films are predicted to increase at 5.9% CAGR over the next ten years.

The global polymer seal market size is projected to reach US$ 12.43 billion in 2024 and at 5.4% CAGR over the next ten years (2024 to 2034). By the end of 2034, global polymer seal demand is forecasted to attain a market revenue of US$ 21.1 billion.

The global graphene market size is calculated at a valuation of US$ 147.4 million for 2024 and is projected to reach US$ 3.85 billion by the end of 2034. Worldwide demand for graphene is forecasted to rise at a jaw-dropping 43% CAGR from 2024 to 2034.

The global small engine market is estimated to be valued at US$ 3,906.6 million in 2024. Projections indicate a steady expansion with a CAGR of 4.3% through 2034. Anticipated growth is set to propel the market to an impressive size of US$ 5,951.7 million by 2034. The growing need for sustainable solution to boost the market demand.